SEC 13F Intelligence

Managers / Q4 2019 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$670M
Q4 2019
Positions
65
Filings on Record
30
2019–present window
Filed
Feb 12, 2020
original filing

Summary

Sectoral Asset Management Inc reported $670M in U.S.-listed holdings across 65 positions for Q4 2019.

Its largest position, Aprea Therapeutics, represents 10.1% of the portfolio.

Compared with Q3 2019, the fund opened 17 new positions and exited 15.

Portfolio Metrics

Turnover
+29.4%
vs prior filed quarter
Top-10 Concentration
+36.6%
share of reported value
Largest Position
+10.1%
Aprea Therapeutics
New / Exited
17 / 15
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 83.1%Other: 15.6%ADR: 1.3%
  • Common Stock · 83.1% · $557M
  • Other · 15.6% · $105M
  • ADR · 1.3% · $8M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
APREA THERAPEUTICSNEW+1.47M1.47M+$67M$67M
RETAEURREATA PHARMACEUTICNEW+80.7K80.7K+$16M$16M
TFXTELEFLEX INCNEW+29.1K29.1K+$11M$11M
CSIIEURCARDIOVASCULAR SYSNEW+205.8K205.8K+$10M$10M
BIIBBIOGEN INCNEW+32.5K32.5K+$10M$10M
AZNNASTRAZENECANEW+157.8K157.8K+$8M$8M
PRAHPRA HEALTH SCIENCENEW+69.9K69.9K+$8M$8M
NXTCEURNEXTCURE INCNEW+125.0K125.0K+$7M$7M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2019

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1APREA THERAPEUTICSCOM10.07%$67M1.47M
2TDOCTELADOC HEALTHhistory →COM3.73%$25M298.7K
3BSXBOSTON SCIENTIFIChistory →COM3.50%$23M518.4K
4TNDMTANDEM DIABETES CAREhistory →COM3.04%$20M341.7K
5AM6AMICUS THERAPEUTICShistory →COM2.99%$20M2.06M
6BMRNBIOMARIN PHARMAC INChistory →COM2.82%$19M223.9K
7AERIEURAERIE PHARMACEUTIChistory →COM2.70%$18M748.6K
8EVHEVOLENT HEALTH INChistory →COM2.70%$18M2.00M
9ATRCATRICURE INChistory →COM2.59%$17M533.8K
10RETAEURREATA PHARMACEUTIChistory →COM2.46%$16M80.7K
11PTCTPTC THERAPEUTICS Ihistory →COM2.36%$16M328.7K
12FGENEURFIBROGEN INChistory →COM2.35%$16M366.8K
13COLLCOLLEGIUM PHARMACEUThistory →COM2.33%$16M757.8K
14INSPINSPIRE MED SYS INChistory →COM2.27%$15M205.0K
15RCMEURR1 RCM INChistory →COM2.24%$15M1.16M
16IMMUIMMUNOMEDICS INChistory →COM2.19%$15M692.1K
17PTLAEURPORTOLA PHARMACEUTIChistory →COM2.16%$14M606.2K
18ASSEMBLY BIOSCIENCESCOM2.11%$14M692.7K
19BMYBRISTOL MYERS SQUIBBhistory →COM2.10%$14M219.5K
20APLSUSDAPELLIS PHARMACEUTIChistory →COM2.08%$14M455.4K
21HRCHILL-ROM HLDS INChistory →COM2.08%$14M122.6K
22GBTUSDGLOBAL BLOOD THERAhistory →COM2.07%$14M174.6K
23VCRAUSDVOCERA COMMUNICATIhistory →COM1.81%$12M585.5K
24TFXTELEFLEX INChistory →COM1.63%$11M29.1K
25STMLEURSTEMLINE THERAPEUThistory →COM1.62%$11M1.02M
26CICIGNA CORPhistory →COM1.59%$11M52.1K
27MRKMERCK & CO INChistory →COM1.54%$10M113.4K
28ALNYALNYLAM PHARMACUETCLhistory →COM1.51%$10M87.6K
29TRHCEURTABULA RASA HEALTHhistory →COM1.50%$10M207.2K
30CSIIEURCARDIOVASCULAR SYShistory →COM1.49%$10M205.8K
31BIIBBIOGEN INChistory →COM1.44%$10M32.5K
32IRTCIRHYTHM TECHNOLOGIEShistory →COM1.40%$9M137.5K
33HMSYHMS HOLDINGS CORPhistory →COM1.33%$9M300.3K
34LLYLILLY ELI & COhistory →COM1.29%$9M65.8K
35AZNNASTRAZENECAhistory →SPONSORED ADR1.17%$8M157.8K
36PRAHPRA HEALTH SCIENCEhistory →COM1.16%$8M69.9K
37ZBHZIMMER BIOMET HLDShistory →COM1.10%$7M49.2K
38SRPTSAREPTA THERAPEUTICShistory →COM1.09%$7M56.8K
39NXTCEURNEXTCURE INChistory →COM1.05%$7M125.0K
40SILKUSDSILK ROAD MEDICALhistory →COM1.03%$7M170.2K
41ABTABBOTT LABShistory →COM1.00%$7M77.2K
42UNIQURE N.V.SHS0.94%$6M87.5K
43MEDTRONIC PLCSHS0.93%$6M55.2K
44ACADACADIA PHARMACEUTCLSCOM0.92%$6M144.4K
45UNHUNITEDHEALTH GRP INCCOM0.91%$6M20.7K
46MOLECULAR TEMPLATESCOM0.90%$6M432.6K
47CHNGUSDCHANGE HEALTHCARE INCOM0.89%$6M362.6K
48AMGNAMGEN INCCOM0.59%$4M16.4K
49TMOTHERMO FISHER SCICOM0.57%$4M11.8K
502655787DBLUEPRINT MEDICINESCOM0.54%$4M45.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.